Related Experiment Video

Updated: May 31, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

STK33 kinase activity is nonessential in KRAS-dependent cancer cells

Carol Babij1, Yihong Zhang, Robert J Kurzeja

  • 1Department of Oncology Research, Amgen Inc., Thousand Oaks, California, USA.

Cancer Research
|July 12, 2011
PubMed

Insights

Targeting serine-threonine kinase 33 (STK33) is not a viable treatment for KRAS-mutant cancers. Studies show STK33 inhibition does not affect KRAS signaling or cancer cell survival, refuting its therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • KRAS mutations are common in human cancers, yet effective targeted therapies are lacking.
  • The serine-threonine kinase STK33 was hypothesized to be essential for KRAS-mutant cancer cell survival.
  • STK33 inhibition was proposed as a potential therapeutic strategy for KRAS-dependent tumors.

Purpose of the Study:

  • To investigate the role of STK33 in the survival of human cancer cells with KRAS mutations.
  • To evaluate the efficacy of STK33 inhibition as a targeted therapy for KRAS-mutant cancers.

Main Methods:

  • Utilized RNA interference and dominant mutant overexpression to assess STK33 function.
  • Conducted a synthetic lethal siRNA screen across various KRAS wild-type and mutant cancer cell lines.
  • Employed small molecule inhibitors targeting STK33 kinase activity, identified via high-throughput screening.

Main Results:

  • Downregulation of KRAS reduced the survival of KRAS-dependent cells, as expected.
  • STK33 downregulation or overexpression did not impact KRAS signaling or cancer cell survival.
  • Synthetic lethal screening identified KRAS, but not STK33, as essential for cell survival.
  • Small molecule inhibitors of STK33 showed no efficacy in relevant cancer models.

Conclusions:

  • STK33 is not required for the survival of KRAS-mutant cancer cells.
  • Inhibition of STK33 is not a therapeutically viable strategy for treating KRAS-dependent tumors.
  • Findings contradict previous hypotheses regarding STK33 as a therapeutic target in oncology.

More Related Videos

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...